Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil

S C L Santos, L R Cavalli, I J Cavalli, R S Lima, B R Haddad, E M S F Ribeiro

See end of article for authors’ affiliations

Correspondence to:
Dr B R Haddad, Institute for Molecular and Human Genetics, Georgetown University Medical Center, 3800 Reservoir Road NW, Main 4000, Washington DC 20007, USA; haddadb1@georgetown.edu

Aim: The evaluation of allelic losses at the FHIT and the BRCA1 genes and at three other loci at the 17q region in a series of 34 sporadic breast cancer cases from Southern Brazil.

Methods: The samples were evaluated for loss of heterozygosity (LOH) at the FHIT and the BRCA1 genes and at three other microsatellite markers at 17q, and the findings were correlated with clinicopathological parameters.

Results: The BRCA1 intragenic marker, D17S855, had the highest frequency of LOH, detected in 10 of 24 informative cases, followed by the D17S579 (six of 23 informative cases), D17S806 (five of 21 informative cases), and D17S785 markers (five of 21 informative cases). LOH at the FHIT intragenic marker, D3S1300, was found in six of 25 informative cases. In four of the six cases with LOH of the FHIT gene, there was concomitant loss of the BRCA1 intragenic marker.

Conclusions: The frequency of allelic losses in the FHIT and BRCA1 loci in the Southern Brazilian population is similar to that described in the general population. No correlations were found when the total LOH frequency was compared with tumour size, grade, or presence of axillary lymph node metastasis. Further studies using larger sporadic breast cancer samples and additional markers would be useful to confirm these findings, in addition to establishing more specific associations with clinicopathological parameters in this specific population.

Breast cancer is the most common malignancy in women and one in eight Brazilian women will probably develop breast cancer in their lifetime. Among the genetic alterations involved in the development and progression of breast cancer, allelic losses at particular chromosomal regions are common, and may indicate deletion of tumour suppressor genes.

Loss of heterozygosity (LOH) at 17q has been reported in about 30–60% of sporadic breast cancer cases and in many studies involves the BRCA1 gene located at 17q21. However, in sporadic breast cancer, somatic mutations inactivating the BRCA1 gene are rare, and it has been suggested that epigenetic mechanisms of inactivation, in addition to LOH at this locus, may take place.

“Among the genetic alterations involved in the development and progression of breast cancer, allelic losses at particular chromosomal regions are common, and may indicate deletion of tumour suppressor genes.”

The region 3p14, where the FHIT gene is located, is a common site for chromosomal rearrangements in breast cancer, and contains the most active common fragile site in the human genome, the FRAS3 locus. Genetic alterations with reduced expression of this gene are found in about 30% of breast cancers. LOH studies have shown allelic losses at 3p14 in about 25% of primary breast carcinomas, suggesting that FHIT may have suppressor-like properties. In familial breast cancer kindreds, early studies demonstrated a higher frequency of allelic imbalance at 3p14 compared with that seen in the sporadic breast cancers. More recent studies in BRCA2 positive tumours have shown a high frequency of FHIT LOH and reduced expression of the FHIT protein.

In our study, we evaluated LOH at the BRCA1 and FHIT loci, in addition to three other loci on 17q, in a series of 34 sporadic breast cancer cases from Southern Brazil. The findings were analysed in relation to clinicopathological parameters.

Materials and Methods

Samples

Primary tumour and peripheral blood specimens were obtained from 34 patients undergoing surgery for sporadic breast cancer at the Hospital Nossa Senhora das Graças and Hospital de Clínicas, Curitiba, Southern Brazil, with informed consent. The patients had no family history of breast cancer and the mean (SD) age was 54.4 (12.5) years. The tumours were classified as grade 2 (17 samples) and grade 3 (17 samples) invasive ductal carcinomas. Table 1 presents the clinicopathological information of the patients.

PCR amplification/LOH analysis

DNA from matched normal and tumour tissues was amplified by the polymerase chain reaction (PCR) using five microsatellite markers with dinucleotide repeats. The following markers were used: D3S1300, intragenic to FHIT on 3p14.2; D17S855, intragenic to BRCA1 at 17q21.3; D17S579 and D17S806 on 17q21.3; and D17S785 on 17q24. The markers were chosen based on their reported high heterozygosity rate. The forward primer for each set was labelled with either of two fluorescent dyes: HEX or FAM (Applied Biosystems/PE Biosystems, Foster City, California, USA).

In all cases the markers were initially evaluated in the DNA from lymphocytes and the informative markers were studied in the tumour tissue. PCR was performed as described previously, using 20 ng/μl of genomic DNA, 100nM Tris/HCl, 500mM KCl, 480nM forward primer and 480nM reverse primer, 200μM dNTPs, and 0.5 unit of Taq polymerase in a total volume of 10 μl. Reactions were cycled as follows: 95°C for five minutes, then 35 cycles of 94°C for 15
seconds, 55°C for 15 seconds, and 72°C for 30 seconds, followed by final elongation at 72°C for 10 minutes.

Allele sizes were determined by electrophoresis of PCR products in 6% denaturing polyacrylamide gels and compared with ROX 500 size standards (Applied Biosystems), using an automated sequencer (ABI 377). The fluorescent signals from the products in 6% denaturing polyacrylamide gels and compared with ROX 500 size standards (Applied Biosystems), using an automated sequencer (ABI 377). The fluorescent signals from the alleles with different sizes were recorded and analysed using the alleles with different sizes were recorded and analysed using GENOTYPER version 2.1 and GENESCAN version 3.1 software (Applied Biosystems). After visual examination of the computer printouts (by two independent observers), LOH was determined mathematically according to the Genotyper User Manual (Applied Biosystems).

Statistical analysis
Significance was determined using $\chi^2$ and t tests to evaluate whether LOH frequency at specific loci was equally distributed among the clinicopathological parameters; p values $< 0.05$ were considered significant.

RESULTS
Specimens from 34 patients with sporadic invasive ductal carcinoma were assessed for LOH at the FHIT and the BRCA1 loci and at three other markers on 17q. Table 1 summarises the results. The BRCA1 intragenic marker, D17S855, showed the highest frequency of LOH (10 of 24 informative cases), followed by the D17S579 (six of 23 informative cases), D17S806 (five of 21 informative cases), and D17S785 markers (five of 21 informative cases). LOH at the FHIT intragenic marker, D351300, was found in six of 25 informative cases. Four of these six cases also had loss of the D17S855 marker. Figure 1 shows examples of losses at the BRCA1 and FHIT genes and at the D17S785 marker. There was no significant difference in the distribution of frequencies of samples that were non-informative, positive, or negative for LOH among the five microsatellite markers ($\chi^2 = 4.64; p > 0.70$).

Clinicopathological associations
In this study, tumours with LOH were equally distributed among the histopathological grade 2 ($\chi^2 = 3.67; p > 0.80$) and 3 ($\chi^2 = 5.44; p > 0.70$) specimens. In addition, no significant difference was found when the LOH frequencies were compared for tumour size ($\leq 2.8$ cm and $> 2.8$ cm; $\chi^2 = 0.36; p > 0.50$). However, when the tumour size was compared between tumours of distinct grades, it was found that grade 3 tumours were larger than grade 2 (mean (SD), 3.32 (1.17) v 2.23 (0.97) cm). This difference was significant using the $t$ test ($t_{16} = 2.87; p < 0.05$).

Women who were $\leq 50$ years of age presented with larger tumours than women $\geq 50$ years ($t_{1} = 5.67; p < 0.05$). As expected, there was no difference when the age of the patients was compared with tumour grades ($t_{1} = 0.47; p > 0.50$) or the presence of metastasis in the axillary lymph nodes ($t_{1} = 0.65; p > 0.30$). Tumours from patients who presented with metastasis in the axillary lymph nodes did not show an increased frequency of LOH when compared with those without metastasis ($t_{1} = 2.44; p > 0.10$).

DISCUSSION
Extensive searches for somatic mutations in the BRCA1 gene at 17q21 have revealed that such mutations are rare in non-familial breast and ovarian cancer, despite the high incidence of LOH at the BRCA1 locus seen in these tumours. Studies have suggested that loci surrounding the BRCA1 gene may be the major targets in 17q deletions. Frequent deletions in breast cancer are found on chromosome arm 3p, mainly at 3p14.2, where the FHIT gene is located, which can lead to LOH at this gene locus. High

### Table 1 Clinicopathological information and LOH analysis results

<table>
<thead>
<tr>
<th>Sample</th>
<th>Histological grade</th>
<th>Tumour size (cm)</th>
<th>Age (years)</th>
<th>Lymph node metastasis</th>
<th>D17S855</th>
<th>D17S579</th>
<th>D17S806</th>
<th>D17S785</th>
<th>D351300</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP 147</td>
<td>IDC grade 2</td>
<td>4.0</td>
<td>35</td>
<td>+</td>
<td>LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 149</td>
<td>IDC grade 2</td>
<td>2.0</td>
<td>60</td>
<td>+</td>
<td>No LOH</td>
<td>NI</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 158</td>
<td>IDC grade 2</td>
<td>2.3</td>
<td>64</td>
<td>+</td>
<td>NI</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 161</td>
<td>IDC grade 2</td>
<td>2.5</td>
<td>54</td>
<td>+</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 165</td>
<td>IDC grade 2</td>
<td>2.0</td>
<td>38</td>
<td>+</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 169</td>
<td>IDC grade 2</td>
<td>1.0</td>
<td>53</td>
<td>Unknown</td>
<td>LOH</td>
<td>Ni</td>
<td>LOH</td>
<td>LOH</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 176</td>
<td>IDC grade 2</td>
<td>1.0</td>
<td>65</td>
<td>-</td>
<td>NI</td>
<td>NI</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 213</td>
<td>IDC grade 2</td>
<td>2.5</td>
<td>58</td>
<td>-</td>
<td>NI</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 227</td>
<td>IDC grade 2</td>
<td>1.0</td>
<td>71</td>
<td>Unknown</td>
<td>NI</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 228</td>
<td>IDC grade 2</td>
<td>1.2</td>
<td>44</td>
<td>-</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>NI</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 229</td>
<td>IDC grade 2</td>
<td>2.0</td>
<td>78</td>
<td>-</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 231</td>
<td>IDC grade 2</td>
<td>2.0</td>
<td>54</td>
<td>+</td>
<td>LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 239</td>
<td>IDC grade 2</td>
<td>3.2</td>
<td>48</td>
<td>-</td>
<td>LOH</td>
<td>LOH</td>
<td>Ni</td>
<td>Ni</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 253</td>
<td>IDC grade 2</td>
<td>3.0</td>
<td>45</td>
<td>+</td>
<td>NI</td>
<td>LOH</td>
<td>LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 255</td>
<td>IDC grade 2</td>
<td>2.0</td>
<td>59</td>
<td>+</td>
<td>NI</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
</tr>
<tr>
<td>CP 257</td>
<td>IDC grade 2</td>
<td>1.7</td>
<td>46</td>
<td>-</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 271</td>
<td>IDC grade 2</td>
<td>4.5</td>
<td>47</td>
<td>+</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>HC 102</td>
<td>IDC grade 3</td>
<td>4.0</td>
<td>55</td>
<td>+</td>
<td>NI</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>HC 146</td>
<td>IDC grade 3</td>
<td>2.2</td>
<td>44</td>
<td>Unknown</td>
<td>NI</td>
<td>LOH</td>
<td>Ni</td>
<td>LOH</td>
<td>NI</td>
</tr>
<tr>
<td>HC 167</td>
<td>IDC grade 3</td>
<td>3.0</td>
<td>45</td>
<td>+</td>
<td>LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 010</td>
<td>IDC grade 3</td>
<td>2.0</td>
<td>65</td>
<td>+</td>
<td>No LOH</td>
<td>LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>NI</td>
</tr>
<tr>
<td>CP 160</td>
<td>IDC grade 3</td>
<td>2.8</td>
<td>54</td>
<td>-</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 183</td>
<td>IDC grade 3</td>
<td>1.5</td>
<td>44</td>
<td>Unknown</td>
<td>Ni</td>
<td>Ni</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
</tr>
<tr>
<td>CP 272</td>
<td>IDC grade 3</td>
<td>3.5</td>
<td>75</td>
<td>-</td>
<td>No LOH</td>
<td>Ni</td>
<td>Ni</td>
<td>No LOH</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 224</td>
<td>IDC grade 3</td>
<td>4.0</td>
<td>76</td>
<td>+</td>
<td>No LOH</td>
<td>LOH</td>
<td>LOH</td>
<td>Ni</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 243</td>
<td>IDC grade 3</td>
<td>4.5</td>
<td>48</td>
<td>+</td>
<td>LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 248</td>
<td>IDC grade 3</td>
<td>4.0</td>
<td>47</td>
<td>Unknown</td>
<td>Ni</td>
<td>LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 252</td>
<td>IDC grade 3</td>
<td>2.8</td>
<td>90</td>
<td>-</td>
<td>Ni</td>
<td>No LOH</td>
<td>LoH</td>
<td>Ni</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 275</td>
<td>IDC grade 3</td>
<td>5.2</td>
<td>45</td>
<td>+</td>
<td>LOH</td>
<td>Ni</td>
<td>Ni</td>
<td>LOH</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 310</td>
<td>IDC grade 3</td>
<td>1.7</td>
<td>53</td>
<td>+</td>
<td>LOH</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 313</td>
<td>IDC grade 3</td>
<td>5.5</td>
<td>49</td>
<td>+</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 318</td>
<td>IDC grade 3</td>
<td>2.0</td>
<td>43</td>
<td>-</td>
<td>LOH</td>
<td>LOH</td>
<td>LOH</td>
<td>LOH</td>
<td>LOH</td>
</tr>
<tr>
<td>CP 331</td>
<td>IDC grade 3</td>
<td>4.2</td>
<td>55</td>
<td>+</td>
<td>No LOH</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>No LOH</td>
</tr>
<tr>
<td>CP 338</td>
<td>IDC grade 3</td>
<td>3.5</td>
<td>42</td>
<td>-</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
<td>Ni</td>
<td>No LOH</td>
</tr>
</tbody>
</table>

IDC, invasive ductal carcinoma; LOH, loss of heterozygosity; NI, not informative.
frequencies of LOH, abnormal transcripts, and reduced expression of the FHIT protein have been observed in invasive breast carcinomas, in addition to some benign breast diseases, suggesting that FHIT alterations are early events in mammary tumorigenesis.11 18 19

In our study, we have assessed LOH at 3p14 (FHIT gene) and three regions of chromosome 17q (17q21.2 (BRCA1 gene), 17q21.3, and 17q24) in patients with sporadic breast cancer. The highest incidence of LOH (42%) was found for the marker D17S855, intragenic to the BRCA1 gene. This finding is in agreement with other studies,7 12 20 supporting the hypothesis that the BRCA1 gene plays an important role in sporadic breast cancer. No significant difference was found for marker D17S855 between grade 2 and grade 3 tumours, suggesting that deletions in the BRCA1 gene probably occur early in mammary carcinogenesis. This result contrasts with data previously reported showing an association between LOH in BRCA1 and grade 3 tumours.21

Similar frequencies of LOH for markers D17S579 and D17S806 were found in other studies in sporadic breast cancer cases.13 The frequencies of LOH observed in this and other reports suggest the presence of other tumour suppressor genes at these regions that may participate in sporadic mammary tumorigenesis. However, we cannot rule out the possibility that the allelic losses in these regions may be a result of partial or total loss of chromosome 17, which is a common cytogenetic abnormality in breast cancer cases.

LOH for the marker D3S1300, intragenic to FHIT, has been reported to occur in frequencies ranging from 24% to 59% in breast cancer.10 11 12 In our study, we detected LOH at this marker in 24% of cases. Of interest was our observation that the marker D17S855 is intragenic to the BRCA1 gene. This finding is in agreement with other studies,7 12 20 supporting the hypothesis that the BRCA1 gene plays an important role in sporadic breast cancer. No significant difference was found for marker D17S855 between grade 2 and grade 3 tumours, suggesting that deletions in the BRCA1 gene probably occur early in mammary carcinogenesis. However, a correlation between the expression of these genes was noted at the protein level by Turner et al.22 These authors found that cases with mutations of the BRCA1 gene also had reduced expression of the FHIT protein, suggesting the necessity of BRCA1 integrity to protect cells from genetic instability at fragile loci, such as FRA3B, where the FHIT gene is located.

"No significant difference was found for marker D17S855 between grade 2 and grade 3 tumours, suggesting that deletions in the BRCA1 gene probably occur early in mammary carcinogenesis."

The frequency of total LOH observed in the analysis of our sporadic breast tumour cases was found to be equally distributed among the tumours classified as grade 2 and grade 3. In addition, no significant difference was found when the LOH frequency was compared for tumour size (< 2.8 cm and > 2.8 cm). However, when tumour size was compared between the two grades of tumours, it was found that grade 3 tumours were larger than grade 2 tumours.

Our study revealed that women < 50 years of age presented with tumours of larger size than women > 50 years, suggesting a faster tumour evolution in younger women. A higher frequency of LOH was also found in the younger group, although this observation did not reach significance by the χ² test. Similar results were reported by Phelan and colleagues14 and Querzoli et al.24 Age and histopathological grades were not associated in this population, corroborating findings by Johnson et al. In addition, we found no increase of the total LOH frequency in grade 3 tumours compared with grade 2 tumours. Previous studies have reported that breast carcinoma in younger women (< 35 years old) usually presents with more aggressive pathological features, such as significantly higher proliferation rates, lack of steroid receptors, and a higher chance of having grade 3 tumours.25

In our cases, the tumours that presented with metastasis to the axillary lymph nodes did not have a higher frequency of LOH. This result is supported by other studies,13 22 25 but contrary to the study of Regnigon et al.,25 who found an association between a higher frequency of LOH at the 17S855 marker and lymph node metastasis in a series of 40 primary sporadic breast tumours and their locally recurrent breast carcinomas.

Although it is important to evaluate breast cancer cases from different ethnic groups to look for the possible presence of unusual changes associated with specific ethnicities, we found no such differences at the markers studied here. Further studies using larger sporadic breast cancer samples and additional markers would be useful to confirm our findings and to establish more specific associations with clinicopathological parameters in our patients.

Take home messages

- The frequency of allelic losses in the FHIT and BRCA1 loci in the Southern Brazilian population is similar to that described in the general population.
- No correlations were found when the total loss of heterozygosity frequency was compared with tumour size, grade, or presence of axillary lymph node metastasis.
- Further studies using larger sporadic breast cancer samples and additional markers would be useful to confirm these findings, and to establish more specific associations with clinicopathological parameters in our patients.
clinical pathological parameters in our specific population of patients from Southern Brazil.

ACKNOWLEDGEMENTS

This work was partially supported by a research grant from CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil). SSL was supported by a scholarship from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior, Brazil).

Authors' affiliations

S C L Santos, I J Cavalli, E M S F Ribeiro, Departamento de Genética, Universidade Federal do Paraná, Curitiba, PR, 81531-970 Brazil
L R Cavalli, B R Haddad, Instituto for Molecular and Human Genetics, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
R S Lima, Departamento de Oncologia, Hospital Nossa Senhora das Graças, Curitiba, PR, 80810-120 Brazil

REFERENCES


Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil

S C L Santos, L R Cavalli, I J Cavalli, R S Lima, B R Haddad and E M S F Ribeiro

J Clin Pathol 2004 57: 374-377
doi: 10.1136/jcp.2003.013490

Updated information and services can be found at:
http://jcp.bmj.com/content/57/4/374

These include:

References
This article cites 24 articles, 6 of which you can access for free at:
http://jcp.bmj.com/content/57/4/374#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Breast cancer (506)
- Molecular genetics (355)
- Immunology (including allergy) (1664)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/